SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
Rhea-AI Summary
SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has announced a webcast and conference call scheduled for August 1, 2024, at 4:30 P.M. ET. The purpose of this event is to provide a business update following the release of the company's second-quarter 2024 financial results. CEO Diem Nguyen and CFO Daniel Luckshire will be participating in the call.
Investors and interested parties can access the live webcast on SIGA's website or dial in using the provided numbers. A replay of the call will be available for two weeks, and the archived webcast will be accessible in the Investor Relations section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SIGA gained 2.98%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 11156004. The archived webcast will be available in the Investor Relations section of the Company's website.
ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.
Contact:
Investors and Media
Suzanne Harnett
InvestorRelationsWeb@siga.com
MediaRelationsWeb@siga.com
FAQ
When will SIGA Technologies (SIGA) release its Q2 2024 financial results?
How can investors access SIGA's Q2 2024 earnings call on August 1, 2024?
Who will be participating in SIGA's Q2 2024 earnings call?
How long will the replay of SIGA's Q2 2024 earnings call be available?
